Where is Summit Therapeutics (SMMT) Headed According to Analysts?

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks with high potential. In a report released on September 29, Leerink Partners maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) without assigning a price target.

Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings

In addition, Barclays also maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on September 25 with a $13 price target.

However, Asthika Goonewardene from Truist Financial maintained a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) the same day, without assigning a price target.

In addition to Asthika Goonewardene, Citi’s Yigal Nochomovitz also expressed bullish sentiments for Summit Therapeutics Inc. (NASDAQ:SMMT) in a report released on September 24, assigning the stock a Buy rating with a $35 price target.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that specializes in creating novel medications for infectious and cancerous diseases.

While we acknowledge the potential of SMMT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SMMT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.